UNSPSC 51111766: Vinblastine

This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C46H58N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V9KLZ54CY, chemically known as 1h-indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2h-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, (3ar-(3aalpha,4beta,5beta,5abeta,9(3r*,5s*,7r*,9s*),10br*,13aalpha))- but generally known as vinblastine, which bears US NIH Compound Identifier 13342.

UNSPSC 51111766 Vinblastine, a Commodity code, nominally designates a specific chemotherapy agent, but recent state and local solicitations tagged under this code show little relevant pharmaceutical procurement activity. The four most recent opportunities posted under this code span naloxone and drug deactivation systems (Seminole County, Florida), a Texas HHS request for information on direct-to-manufacturer prescription programs, Tampa Fire Department medical and first aid supplies including emergency response consumables, and a Minnesota multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products. Only the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products bears any nominal connection to pharmaceutical supply; the others target emergency response supplies, naloxone acquisition, and pharmacy program strategy rather than chemotherapy or specialty oncology agents. The issuing bodies include county health departments, state HHS agencies, municipal fire departments, and multistate cooperative purchasing alliances—a fragmented mix that does not reflect coherent demand for the specific product named by the code.

Activity appears scattered across Florida, Texas, Minnesota, and Oregon (the latter through MMCAP participation), with no geographic concentration. The Seminole County naloxone procurement (IFB60459723LAS, due July 26, 2023, though the posting date of June 30, 2026 suggests a data inconsistency) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually. The City of Tampa's medical and first aid supplies bid (26P00145, due March 13, 2026, sheltered for certified Small Local Business Enterprises with a $700,000 estimated contract value) covers 169 line items for the Fire Department Rescue Division. The Minnesota MMCAP RFP (S1070000015802, proposals due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities, with pricing weighted at 75 percent and awards effective July 1, 2026. The mismatch between the code's nominal scope (vinblastine, a specific chemotherapy drug) and the actual procurements suggests that state and local tagging practices may not align precisely with this Commodity code, limiting its utility as a signal for oncology pharmaceutical opportunity.